NCT07518979: EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant Treatment of Advanced Penile Cancer
- State
- Under way
- Phase
- Phase 2
- People
- 60 planned
- Started
- 22 Jul 2026
- Primary completion
- 1 May 2028
- Arms
- Becotatug Vedotin + Pucotenlimab Neoadjuvant Arm
- Results
- None posted
- 9 Apr 2026: Trial registered
- 22 Jul 2026: Trial started